On April 18, President Trump signed an executive order directing the FDA to accelerate access to psychedelic therapies, with veterans' mental health and the PTSD crisis as the headline justification. The question worth asking is which publicly traded companies actually benefit most urgently, and at what point in time.
The mechanism at the center of the order is the Commissioner's National Priority Voucher, which compresses FDA review timelines from years to weeks. The language is clear on eligibility: a compound must hold Breakthrough Therapy designation and meet the criteria of the National Priority Voucher Program. Breakthrough designation requires Phase 2 data demonstrating substantial improvement over existing therapies in an area of unmet need. The voucher is therefore not a reward for promise, it is a reward for demonstrated late-stage efficacy.
That logic produces a short list.
Compass Pathways (CMPS) is the most immediate beneficiary. COMP360 has delivered two highly statistically significant Phase 3 results across the COMP005 and COMP006 trials, both using change in MADRS scores at week six as the primary endpoint. COMP005 enrolled 258 participants across 32 US sites, with a single 25 mg dose producing a mean MADRS difference of -3.6 versus placebo (p<0.001). COMP006 enrolled 568 participants across North America and Europe, with two doses administered three weeks apart producing a mean difference of -3.8 versus the 1 mg control (p<0.001), with onset as early as the day following administration and durability through at least six months. The dataset has been submitted to the FDA under a rolling NDA review, with full submission expected in Q4 2026. The voucher is deployable now.
Helus Pharma (HELP) holds breakthrough designation for HLP003, a deuterated novel serotonergic agonist developed as an adjunctive treatment for MDD. Phase 2 data from two doses of 16 mg produced 100% response rates and 71% remission at 12 months, with a mean approximately 23-point reduction in MADRS from a baseline of around 32, and no serious adverse events across the 12-month follow-up. HLP003 is currently dosing in the PARADIGM Phase 3 program, which comprises two pivotal studies, APPROACH and EMBRACE, and a long-term extension, EXTEND. Topline data from APPROACH is anticipated in Q4 2026. Like Compass, Helus is one strong Phase 3 readout away from having a complete package, making it the second name on the express lane, one catalyst behind.
“The voucher is therefore not a reward for promise, it is a reward for demonstrated late-stage efficacy.”
Definium Therapeutics (DFTX) holds breakthrough designation for DT120 in generalized anxiety disorder, with Phase 3 readouts expected across 2026. The voucher becomes relevant once that data lands, making Definium a second-order beneficiary, significant but not immediate.
AtaiBeckley (ATAI) is initiating Phase 3 for BPL-003, its intranasal mebufotenin formulation, in Q2 2026 following a successful end-of-Phase 2 FDA meeting. Breakthrough designation was granted in October 2025. Phase 3 topline data is years away, placing ATAI in the tailwind category rather than the express lane.
The executive order matters beyond the voucher. The ibogaine IND clearance it unlocked, the ARPA-H (Advanced Research Projects Agency for Health, the federal agency modeled on DARPA and created in 2022 to fund high-risk biomedical innovation) matching mechanism, seeded at $50 million, and the broader signal that the White House views psychedelic compounds as a policy priority all reduce friction across the pipeline. But when it comes to the companies that can pull the trigger on expedited review today, the list is short: CMPS and HELP first, DFTX close behind, ATAI watching from Phase 3 entry.
The ibogaine story deserves separate attention. The order specifically names ibogaine compounds, and FDA Commissioner Martin Makary announced ibogaine's first IND clearance on the same day, opening the door to US clinical trials for the first time. The political framing here is veterans and the suicide crisis, with the administration citing ibogaine's striking early data in opioid addiction and PTSD, including a Stanford study showing dramatic reductions in PTSD symptoms and suicidal ideation in active-duty special operations soldiers. The ARPA-H matching mechanism will most immediately benefit Texas's ibogaine research program, which carved out the same amount in state funding last year. Ibogaine is not psilocybin, it is pharmacologically distinct, carrying cardiac risks that complicate its clinical development path. But with federal funding now unlocked and IND clearance granted, the compound moves from a regulatory dead zone to an active development space almost overnight. The near-term beneficiaries there are largely private and academic, but the longer arc points toward a new publicly traded entrant in the ibogaine space within the next few years.
References
- White House Fact Sheet: Accelerating Medical Treatments for Serious Mental Illness, April 18, 2026
- Compass Pathways expects earlier FDA approval decision on COMP360, Compass Pathways press release, 2026
- Helus Pharma's HLP003 is a Deuterated Novel Serotonergic Agonist Program with FDA Breakthrough Therapy Designation, Helus Pharma press release, 2026
- DT120 granted Breakthrough Therapy Designation from FDA, Definium Therapeutics press release, 2026
- AtaiBeckley BPL-003 Phase 3 program initiation on track for Q2 2026, GlobeNewswire, March 10, 2026
- FDA awards first-ever National Priority Vouchers, FDA press release, February 2026
- Psychedelic Drug Development Tracker, Psychedelic Alpha, 2026
- Ibogaine and PTSD in special operations soldiers, Stanford University study